US 12,006,553 B2
Companion diagnostics for mitochondrial inhibitors
Michael P. Lisanti, Fulton, MD (US); and Federica Sotgia, Fulton, MD (US)
Assigned to LUNELLA BIOTECH, INC., Ontario (CA)
Appl. No. 16/614,581
Filed by LUNELLA BIOTECH, INC., Ottawa (CA)
PCT Filed May 18, 2018, PCT No. PCT/US2018/033488
§ 371(c)(1), (2) Date Nov. 18, 2019,
PCT Pub. No. WO2018/213764, PCT Pub. Date Nov. 22, 2018.
Claims priority of provisional application 62/590,432, filed on Nov. 24, 2017.
Claims priority of provisional application 62/576,287, filed on Oct. 24, 2017.
Claims priority of provisional application 62/529,871, filed on Jul. 7, 2017.
Claims priority of provisional application 62/524,829, filed on Jun. 26, 2017.
Claims priority of provisional application 62/508,750, filed on May 19, 2017.
Claims priority of provisional application 62/508,799, filed on May 19, 2017.
Claims priority of provisional application 62/508,788, filed on May 19, 2017.
Claims priority of provisional application 62/508,769, filed on May 19, 2017.
Claims priority of application No. PCT/US2018/022403 (WO), filed on Mar. 14, 2018.
Prior Publication US 2020/0255902 A1, Aug. 13, 2020
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6816 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6816 (2013.01); C12Q 2565/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 9 Claims
 
1. A method for treating breast cancer in a breast cancer patient having mRNA levels of at least one of HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker, the method comprising:
obtaining a breast tumor sample obtained from a breast cancer patient having measured mRNA levels of at least one of HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker;
measuring an mRNA level of each of a plurality of mitochondrial markers in the breast tumor sample, the plurality comprising HSPD1, UQCRB, MRPL15, and COX17; and
administering to the breast cancer patient having measured mRNA levels of at least one of the HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker, a pharmaceutically effective amount of a mitochondrial inhibitor, the mitochondrial inhibitor selected from the group consisting of a mitoriboscin, a mitoketoscin, an antimitoscin, metformin, a tetracycline family member, an erythromycin family member, atovaquone, bedaquiline, and vitamin c.